Moving promising therapeutics into practice

Nicknamed the “valley of death” by insiders, the gap between academic discovery and drug development is where most good ideas for new drugs fall to the wayside. A commercial drug developer turned academic researcher, Zhiqiang An, Ph.D., has worked on both sides.

After 15 years in the pharmaceutical and biotechnology industry, mostly at Merck Research Laboratories, An was recruited to lead the Texas Therapeutics Institute (TTI), an academic drug discovery center at The University of Texas Health Science Center at Houston (UTHealth).

Read More »